A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema

Trial Profile

A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema

Completed
Phase of Trial: Phase III

Latest Information Update: 25 May 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Diabetic macular oedema
  • Focus Registrational; Therapeutic Use
  • Acronyms VIVID-EAST; VIVID-EAST-DME
  • Sponsors Bayer
  • Most Recent Events

    • 29 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 07 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 Jun 2014 According to a Bayer HealthCare media release, the European Committee for Medicinal Products for Human Use (CHMP) has recommended aflibercept solution for approval for the treatment of visual impairment due to diabetic macular edema.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top